SI-BONE, Inc. Names Noted Spine Surgeon, Steven R. Garfin, M.D., as Chair of Medical Advisory Board
Dr. Garfin to focus on sacroiliac joint dysfunction diagnostic algorithm and process to educate surgeons on minimally invasive treatment options
CUPERTINO, Calif., Oct. 26 /PRNewswire/ -- SI-BONE, Inc. (Cupertino, California) announced today that Steven R. Garfin, Professor and Chairman of Orthopedics Department at University of California, San Diego, has become the chair of the SI-BONE Medical Advisory Board. Dr. Garfin is a Board Certified Spine Surgeon who is a past president of the North American Spine Society (NASS) and Cervical Spine Research Society (CSRS) and is one of the most respected spine surgeons in the United States. Dr. Garfin's impressive published research and writing include: author of nine books, 123 book chapters, 255 peer-reviewed journal articles, and 132 abstracts.
Dr. Garfin chaired the Sept. 3rd SI Joint Diagnostic Summit sponsored by SI-BONE, where notable spine surgeons met to determine a best consensus algorithm for evaluation of symptomatic patients with SI Joint pathology. The Summit findings related to the diagnosis of SI Joint dysfunction have been drafted in a manuscript on SI Joint Diagnosis for submission to a peer-reviewed spine journal. "The SI Joint has been thought by many to be relatively unimportant as related to the cause of low back symptoms, including pain and disability," said Steve Garfin, M.D. "The initial research presented by surgeons and other clinicians at the Summit strongly suggests it is a real cause and may be a contributor to low back complaints and disability. The SI joint supports essentially all the weight of the spine."
"I concur with Dr. Garfin that the Summit findings could have very interesting implications for low back diagnoses and spine surgery," according to A. Nick Shamie, MD, Associate Professor of Orthopedic and Neurosurgery at UCLA Comprehensive Spine Center, and a member of the SI-BONE Medical Advisory Board. "The more we know about what the SI Joint does and its various pathologies, the better we can devise therapeutic interventions after physical therapy fails." Dr. Nick Shamie is a Board Certified Spine Surgeon on the UCLA School of Medicine faculty since 2000. Dr. Shamie is actively involved in basic science and clinical research in the field of Spine Surgery.
According to Mark Reiley, M.D., SI-BONE Co-founder and Chief Medical Officer, "The participation of Dr. Garfin as Chair and Dr. Shamie as Member of the SI-BONE Medical Advisory Board provides us with the extensive experience required to shape our understanding of SI Joint pathology and diagnoses, as well as our development of minimally invasive treatment strategies and products for spine surgeons."
Dr. Garfin explained that his acceptance of the SI-BONE Medical Advisory Board leadership position demonstrates his commitment to guiding the clinical research process. "It will be a process that will yield new insights, understanding, and strategies for spine surgeons seeking to deal with unresolved, chronic low back symptoms that may be related to SI Joint pathology. The lower back can be vulnerable to many pain-causing injuries or disorders related to SI Joint pathology because it carries much of the body weight and is subject to the most force and stress from the spine."
In response to increasing awareness of SI Joint dysfunction as a debilitating symptom generator, SI-BONE, Inc. developed an innovative, patented, intramedullary implant to treat the SI Joint. Surgeons in numerous locations throughout the country are performing iFuse surgery. The company is also planning a post-market multicenter study to determine its effect over time on SI Joint pathology and on symptoms associated with SI Joint dysfunction.
The iFuse Implant System is a commercially available device in the US intended for fracture fixation of large bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. Having a small incision surgical option to treat an unmet clinical need like SI Joint Dysfunction should prove to be an enormous benefit to both patients and surgeons alike. The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants. The implants are coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion. These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional pins or screws used to surgically fix boney structures. The implant technology from SI-BONE has been previously used successfully in approximately 1,000 cases of dysfunctional foot joints and was cleared for marketing for the sacroiliac joint in November 2008.
About SI-BONE, Inc.
SI-BONE, Inc. (Cupertino, California) is a leading spinal medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to sacroiliac (SI) joint pathology. The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of SI Joint pathology. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices. The company's goal is to help surgeons improve lives through its proprietary technology. Please visit www.si-bone.com.
SOURCE SI-BONE, Inc.
More by this Source
AMA CPT Editorial Panel Votes to Make MIS SI Joint Fusion a Category I Procedure
Mar 06, 2014, 07:00 ET
SI-BONE, Inc. Announces Medicare Palmetto Removes MIS SI Joint Fusion from Non-Coverage
Feb 25, 2014, 07:00 ET
SI-BONE, Inc. annuncia il raggiungimento di 10.000 procedure iFuse
Jan 07, 2014, 16:17 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.